drugset / Trial / NCT05639179
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
Phase 1/2
Unknown
30 enrolled
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of UCAR-T Cells injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).
Timeline
- Start
- 2022-12-05
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UCAR T-cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | UCAR T-cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | UCAR T-cells | Cell therapy | 5e+06 cells/kg | Intravenous |